/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
CALGARY, June 21, 2017 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) today confirmed, as announced on June 20, 2017, that its
previously-announced equity offering closed as previously scheduled on June 20, 2017, issuing a
total of $10 million of its equity units. A June 20, 2017 TSX Trader
Note stated that the closing had been delayed. A second June 20, 2017 TSX Trader Note published
shortly thereafter stated that the equity offering had closed, however certain outlets did not communicate the second TSX Trader
Note to their users.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and
extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4.
This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits
for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's
disease, Fabry disease, other orphan diseases, and peripheral artery disease, while maintaining a well described safety profile.
Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a
Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be
initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients
with end-stage renal disease treated with hemodialysis.
Resverlogix common shares and warrants trade on the Toronto Stock Exchange (TSX:RVX and RVX.WT).
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone
in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, Alzheimer's disease,
Fabry disease, and Orphan diseases. Our actual results, events or developments could be materially different from those expressed
or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those
discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available
through SEDAR at www.sedar.com. The forward-looking statements contained in
this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims
any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
SOURCE Resverlogix Corp.
View original content: http://www.newswire.ca/en/releases/archive/June2017/21/c5013.html